Stock Update (NYSE:GE): LeukoDx and GE Healthcare Enter Agreement to Explore Solutions for Cell Characterization in Cell Therapy Manufacturing

[Marketwired] – LeukoDx, an emerging leader in the field of fully-automated cell-based assays, and GE Healthcare’s Life Sciences business, a provider of technologies and expertise to the biopharmaceutical and life sciences … Read more on this. General Electric Company (GE) , valued at $284.96B, started trading this morning at $30.04. Today, shares have traded between $30.13 and $30.29 per share and has traded between $19.37 and $31.49 over the past year. Priced at 20.18x this year’s forecasted earnings, GE shares are relatively expensive compared to the industry’s 14.83x forward p/e ratio. The company pays shareholders $0.92 per share annually in dividends, yielding 3.03%. Consensus earnings for the current quarter by the 14 sell-side analysts covering the stock is an estimate of $0.19 per share, which would be $0.01 worse than the year-ago quarter and a $0.08 sequential decrease. Investors should also note that the full-year EPS estimate of $1.50 is a $0.19 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $28.21 Billion. If reported, that would be a 3.92% decrease over the year-ago quarter. Recently, UBS Initiated GE at Buy (Jan 22, 2015). Previously, RBC Capital Mkts Initiated GE at to Outperform. When considering if perhaps the stock is under or overvalued, the average price target is $32.54, which is 8.32% above where the stock opened this morning. See more in (NYSE:GE) Similar Articles: Company Update: General Electric Company (NYSE:GE) – 81% of Consumers are Unsatisfied with their Healthcare Experience, According to a New Study by Prophet and GE Healthcare Camden Group Company Update (NYSE:GE): Diamond Offshore and GE Oil & Gas Enter into Industry’s First Performance-Based Subsea Blowout Preventer Service Agreement Stock Update: General Electric Company (NYSE:GE) – Top 2016 Healthcare Trends Predicted by GE Healthcare Camden Group